155
The development of an IgG lambda - type monoclonal gammopathy and subsequent multiple myeloma in an epilepsy patient on diphenylhydantoin ( DILANTIN ) therapy for 20 years is reported .
 adverse effect: IgG lambda - type monoclonal gammopathy, DILANTIN; adverse effect: IgG lambda - type monoclonal gammopathy, diphenylhydantoin; adverse effect: multiple myeloma, DILANTIN; adverse effect: multiple myeloma, diphenylhydantoin
Given options, please tell me the relationships of all the listed entity pairs.Output format is "relation1: word1, word2; relation2: word3, word4". 
Option: adverse effect 
Text: {0} 
 Entity Pairs:  IgG lambda - type monoclonal gammopathy, DILANTIN; IgG lambda - type monoclonal gammopathy, diphenylhydantoin; multiple myeloma, DILANTIN; multiple myeloma, diphenylhydantoin 
Answer:
 adverse effect: IgG lambda - type monoclonal gammopathy, DILANTIN; adverse effect: IgG lambda - type monoclonal gammopathy, diphenylhydantoin; adverse effect: multiple myeloma, DILANTIN; adverse effect: multiple myeloma, diphenylhydantoin